Payment overview · 2025
General Payments
$1,259.44
75 reported records · 16 companies
Healthcare provider profile · identity verified
Tabassum Hatimi, MD
Allopathic & Osteopathic Physicians|Family Medicine · ANDERSON, IN · NPI 1881652022
Verified facts
What the public records show
CMS Open Payments records show Tabassum Hatimi, MD received $1,259.44 in general payments during 2025 across 75 reported records.
PFIZER INC. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 420 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $244.29 | 19.4% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.04 | 16.8% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $184.39 | 14.6% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $147.31 | 11.7% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $83.31 | 6.6% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$75.80 | 6.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $57.81 | 4.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.55 | 3.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.34 | 3.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.59 | 2.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.04 | 2.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.97 | 2.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.84 | 1.6% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $19.64 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.62 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.90 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,259.44 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $168.15 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $167.64 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $147.86 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $137.55 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $101.71 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $83.31 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $82.68 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $82.68 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $76.65 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $76.65 | 7 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $75.80 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.58 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.18 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.59 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.00 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $43.34 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.34 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.03 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.59 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.04 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.97 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 103 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 420 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 117 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
86 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | 12 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
103 | 102 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
420 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 963 | 233 |
| Levothyroxine Sodium | Levothyroxine Sodium | 739 | 137 |
| Gabapentin | Gabapentin | 623 | 127 |
| Montelukast Sodium | Montelukast Sodium | 506 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 116 |
| Eliquis | Apixaban | 420 | 58 |
| Losartan Potassium | Losartan Potassium | 349 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 346 | 85 |
| Lisinopril | Lisinopril | 330 | 75 |
| Potassium Chloride | Potassium Chloride | 318 | 69 |
| Omeprazole | Omeprazole | 301 | 70 |
| Trazodone Hcl | Trazodone Hcl | 289 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 272 | 55 |
| Buspirone Hcl | Buspirone Hcl | 257 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 68 |
| Tizanidine Hcl | Tizanidine Hcl | 253 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 213 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 71 |
| Metformin Hcl | Metformin Hcl | 205 | 46 |
| Spironolactone | Spironolactone | 196 | 55 |
| Sertraline Hcl | Sertraline Hcl | 187 | 39 |
| Alendronate Sodium | Alendronate Sodium | 180 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 46 |
| Simvastatin | Simvastatin | 173 | 38 |
| Furosemide | Furosemide | 171 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 161 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 76 |
| Metformin Hcl Er | Metformin Hcl | 141 | 45 |
| Carvedilol | Carvedilol | 137 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 40 |
| Torsemide | Torsemide | 126 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 123 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 119 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 26 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 117 | 28 |
| Ozempic | Semaglutide | 117 | 23 |
| Prednisone | Prednisone | 114 | 81 |
| Allopurinol | Allopurinol | 110 | 23 |
| Jardiance | Empagliflozin | 110 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 103 | 102 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 28 |
| Bupropion Xl | Bupropion Hcl | 95 | 28 |
| Donepezil Hcl | Donepezil Hcl | 93 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 15 |
| Linzess | Linaclotide | 86 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | 19 |
| Insulin Lispro | Insulin Lispro | 82 | 15 |
| Glimepiride | Glimepiride | 81 | 19 |
| Mirtazapine | Mirtazapine | 79 | 22 |
| Ezetimibe | Ezetimibe | 77 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 77 | 13 |
| Tramadol Hcl | Tramadol Hcl | 76 | 17 |
| Alprazolam | Alprazolam | 75 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 67 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 67 | 31 |
| Pregabalin | Pregabalin | 67 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 67 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 30 |
| Baclofen | Baclofen | 58 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 33 |
| Lidocaine | Lidocaine | 58 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | suppressed |
| Nystatin | Nystatin | 54 | 25 |
| Rexulti | Brexpiprazole | 54 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 45 |
| Ketoconazole | Ketoconazole | 51 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 11 |
| Aripiprazole | Aripiprazole | 48 | 12 |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Lubiprostone | Lubiprostone | 48 | 17 |
| Nabumetone | Nabumetone | 48 | 13 |
| Memantine Hcl | Memantine Hcl | 47 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Famotidine | Famotidine | 46 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 12 |
| Methocarbamol | Methocarbamol | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 43 | 25 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 43 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 16 |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 12 |
| Scopolamine | Scopolamine | 40 | 12 |
| Tradjenta | Linagliptin | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 38 | 13 |
| Meloxicam | Meloxicam | 38 | 18 |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 37 | 16 |
| Valsartan | Valsartan | 37 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Trulicity | Dulaglutide | 34 | 12 |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Enulose | Lactulose | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 26 |
| Estradiol | Estradiol | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lactulose | Lactulose | 30 | 22 |
| Ondansetron Odt | Ondansetron | 30 | 18 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Clotrimazole | Clotrimazole | 28 | 19 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 28 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Metronidazole | Metronidazole | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Ceftriaxone | Ceftriaxone Sodium | 24 | 17 |
| Lidocaine Hcl | Lidocaine Hcl/Pf | 24 | 15 |
| Cephalexin | Cephalexin | 23 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 17 | suppressed |
| Pentasa | Mesalamine | 17 | suppressed |
| Veozah | Fezolinetant | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 13 |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Avapro | Irbesartan | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,259.44 · 75 records | PFIZER INC. | ABRYSVO, AIRSUPRA, Auvelity, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, INTELLIS ADAPTIVESTIM, JARDIANCE, Kerendia, LOREEV XR, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error